Tibolone: the way to beat many a postmenopausal ailments

Bibliography

• Kloosterboer HJ. Tissue-selectivity: the mechanism of action of tibolone. Maturitas 2004;48(Suppl):S30-40
   PubMed Web of Science ®Google Scholar
• Kloosterboer HJ. Tissue-selective effects of tibolone on the breast. Maturitas 2004;49(suppl):S5-15
   PubMed Web of Science ®Google Scholar
• Kloosterboer HJ. Tibolone: a steroid with a tissue-specific mode of action. J Steroid Biochem Mol Biol 2001;76:231-8
   PubMed Web of Science ®Google Scholar
• Gruber CJ, Tschugguel W, Schneeburger C, Huber JC. Production and actions of estrogens. N Engl J Med 2002;346:340-52
   PubMed Web of Science ®Google Scholar
• Markiewicz L, Gurpide E. In vitro evaluation of estrogenic, estrogen antagonistic and progestagenic effects of a steroidal drug (Org OD-14) and its metabolites on human endometrium. J Steroid Biochem 1990;35:535-41
   PubMedGoogle Scholar
• Verhoeven CH, Vos RM. Delbressine LP. The in vivo metabolism of tibolone in animal species. Eur J Drug Metab Pharmacokinet 2002;27:1-10
   PubMedGoogle Scholar
• Timmer CJ, Verheul HAM, Doorstam DP. Pharmacokinetics of tibolone in early and late postmenopausal women. J Clin Pharmacol 2002;54:101-6
   Google Scholar
• Vos RM, Krebbers SF, Verhoeven CH. Delbressine LP. The in vivo human metabolism of tibolone. Drug Metab Dispos 2002;30:106-12
   PubMed Web of Science ®Google Scholar
• Falany JL, Masrina N, Falany CN. Sulfation of tibolone and tibolone metabolites by expressed human cytosolic sulfotransferases. J Steroid Biochem Mol Biol 2004;88:383-91
   PubMed Web of Science ®Google Scholar
• Timmer LJ, Houwing NS. Dose proportionality of three different doses of tibolone. Pharmacotherapy 2002;22:106-12
   Google Scholar
• Stearns V, Ullmer L, Lopez J, et al. Hot flushes. Lancet 2002;360(9348):1851-61
   PubMed Web of Science ®Google Scholar
• Osterlund MK, Hurd YL. Estrogen receptors in the human forebrain and the relation to neuropsychiatric disorders. Prog Neurobiol 2001;64:251-67
   PubMed Web of Science ®Google Scholar
• Fernandez-Guasti A, Kruijver Fodor M, Swaab DF. Sex differences in the distribution of androgen receptors in the human hypothalamus. J Comp Neurol 2000;425:422-35
   PubMed Web of Science ®Google Scholar
• Stahl SM. Effects of estrogen on the central nervous system. J Clin Psychiatry 2001;62(5):317-8
   PubMedGoogle Scholar
• Casper RF, Yes SS. Neuroendocrinology of menopausal flushes: an hypothesis of flush mechanism. Clin Endocrinol (Oxf) 1985;22(3):293-312
   PubMed Web of Science ®Google Scholar
• Shaver JL. Beyond hormonal therapies in menopause. Exp Gerontol 1994;29(3-4):469-76
   PubMed Web of Science ®Google Scholar
• Landgren MB, Helmond FA, Engelen S. Tibolone relieves climacteric symptoms in highly symptomatic women with at least seven hot flushes and sweats per day. Maturitas 2005;50:222-30
   PubMed Web of Science ®Google Scholar
• Genazzani AR, Petraglia F, Genazzani AD, et al. Effects of Org OD 14 on pituitary and peripheral β-endorphin in castrated rats and post-menopausal women. Maturitas (Suppl) 1987;1:35-48
   PubMedGoogle Scholar
• Winkler UH, Alskemper R, Kwee B, et al. Effects of tibolone and continuous combined hormone replacement therapy on parameters in the clotting cascade: a multicenter, double-blind, randomized study. Fertil Steril 2000;74:10-9
   PubMed Web of Science ®Google Scholar
• Huber J, Palacios S, Berglund L, et al. Effects of tibolone and continuous combined hormone replacement therapy on bleeding rates, quality of life and tolerability in postmenopausal women. Br J Obstet Gynaecol 2002;109:886-93
   Google Scholar
• Simon JA. Estrogen replacement therapy: effects on the endogenous androgen milieu. Fertil Steril 2002;(Suppl 4):77-88
   PubMedGoogle Scholar
• Davis S, Burger H. Use of androgens in postmenopausal women. Curr Opin Obstet Gynecol 1997;9:177-80
   PubMed Web of Science ®Google Scholar
• Davis S, Burger H. Clinical review 82: androgens and the postmenopausal woman. J Clin Endocrinol Metab 1996;81:2759-63
   PubMed Web of Science ®Google Scholar
• Dören M, Ruebig A, Holzgreve W. Defferential effects on the androgen status of postmenopausal women treated with tibolone and continuous combined estradiol and norethindrone acetate replacement therapy. Fertil Steril 2001;75:554-8
   PubMed Web of Science ®Google Scholar
• Notelovitz M. Androgen effects on bone and muscle. Fertil Steril 2002;77(4):34-41
   PubMed Web of Science ®Google Scholar
• Abu EO, Horner A, Kurec V, et al. The localization of androgen receptors in human bone. J Clin Endocrinol Metab 1997;82:3493-7
   PubMed Web of Science ®Google Scholar
• MacNamara P, Loughrey HC. Progesterone receptor A and B isoform expression in human osteoblasts. Calcif Tissue 1998;63:39-46
   PubMedGoogle Scholar
• Sunyer T, Lewis J, Collin-Osdoby P, Osdoby P. Estrogen's bone protective effect may involve differential IL-1 receptor regulation in human osteoblast-like cells. J Clin Invest 1999;103:1409-18
   PubMed Web of Science ®Google Scholar
• Verborgt O, Gibson GJ, Schaffer MB. Loss of osteocytes integrity with microdamage and bone remodeling after fatigue in vivo. J Bone Miner Res 2000;15:60-7
   PubMed Web of Science ®Google Scholar
• Bord S, Horner A, Beavan S, Compston J. Estrogen receptors á and beta are differential expressed in developing human bone. J Clin Endocrinol Metab 2001;86:2309-14
   PubMed Web of Science ®Google Scholar
• Janssen JM, Bland R, Hewison M, et al. Estradiol formation by human osteoblasts via multiple pathways: relation with osteoblast function. J Cell Biol 1999;75:528-37
   Google Scholar
• Genazzani A, Benedek-Jaszmann DM, Andolsek L, et al. Org OD 14 and the endometrium. Maturitas 1991;13:243-51
   PubMed Web of Science ®Google Scholar
• Lloyd G, McGing A, Patel N, et al. A randomised placebo controlled trial of the effects of tibolone on blood pressure and lipids in hypertensive women. J Hum Hypertens 2000;14:99-104
   PubMed Web of Science ®Google Scholar
• Parkin D, Smith F, Lindsay R, Hart DM. Effects of long-term Org OD 14 administration on blood coagulation in climacteric women. Maturitas 1999;9:95-101
   Google Scholar
• Cortes-Prieto J. Coagulation and fibrinolysis in post-menopausal women treated with Org OD 14. Maturitas 1987;1:67-72
   PubMedGoogle Scholar
• Dören M, Rübig HJ, Holzgreve W. Resistance of pelvic arteries and plasma lipids in postmenopausal women: comparative study of tibolone and continuous combined estradiol and norethindrone acetate replacement therapy. Am J Obstet Gynecol 2000;183:575-82
   PubMed Web of Science ®Google Scholar
• Bjarnason N, Bjarnason KH, Bennink HJ, Christiansen C. Tibolone: influence on markers of cardiovascular disease. J Clin Endocrinol Metab 1997;82:1752-6
   PubMed Web of Science ®Google Scholar
• Walker I, Davidson A, Yates R, McEwan HP. The effect of the synthetic steroid Org OD14 on fibrinolysis and blood lipids in postmenopausal women. Thromb Haemost 1985;53:303-5
   PubMed Web of Science ®Google Scholar
• Berning B, Kuijk JW, Bennink HJ. Effects of two doses of tibolone on trabecular and cortical bone loss in early postmenopausal women: a two-year randomized, placebo-controlled study. Bone 1996;19:395-9
   PubMed Web of Science ®Google Scholar
• Berning B, van Kuijk HJ, Fauser BC. Absent correlation between vaginal bleeding and oestradiol levels or endometrial morphology during tibolone use in early postmenopausal women. Maturitas 2000;35:81-8
   PubMed Web of Science ®Google Scholar
• Bjarnason N, Bjarnason J, Rosenquist C, Christiansen C. Tibolone: prevention of bone loss in late postmenopausal women. J Clin Endocrinol Metab 1996;81:2419-22
   PubMed Web of Science ®Google Scholar
• Gallagher JC, Baylink DJ, Freeman R, McClung M. Prevention of bone loss with tibolone in postmenopausal women. Results of two randomized, double-blind placebo-controlled, dose-finding studies. J Clin Endocrinol Metab 2001;86:4717-26
   PubMed Web of Science ®Google Scholar
• Lazovic G, Radivojevic U, Milosevic V, et al. Tibolone and osteoporosis. Arch Gynecol Obstet 2007;276(6):577-81
   PubMedGoogle Scholar
• Ettinger B. Tibolone for prevention and treatment of postmenopausal osteoporosis. Maturitas 2007;57:35-8
   PubMedGoogle Scholar
• Archer DF, MacIntyre-Seltman K, Wilborn WW, et al. Endometrial morphology in asymptomatic postmenopausal women. Am J Obstet Gynecol 1991;165:317-20
   PubMed Web of Science ®Google Scholar
• Pickar JH, Archer DF. Is bleeding a predictor of endometrial hyperplasia in postmenopausal women receiving hormone replacement therapy. Am J Obstet Gynecol 1997;177:1178-83
   PubMed Web of Science ®Google Scholar
• Schatz F, Kuczynski E, Kloosterboer HJ, et al. Tibolone and its metabolites enhance tissue factor and PAI-1 expression in human endometrial stromal cells: evidence of progestogenic effects. Steroids 2005;70:840-5
   PubMed Web of Science ®Google Scholar
• Million Women Study Collaborators. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 2005;365:1543-51
   PubMed Web of Science ®Google Scholar
• De Vries C, Bromley S, Thomas H. Tibolone and endomentrial cancer. A cohort and nested case-control study in the UK. Drug Saf 2005;28(3):241-9
   PubMed Web of Science ®Google Scholar
• Acher DF, Hendrix S, Callagher JC, et al. Endometrial effects of tibolone. J Clin Endocrinol Metab 2007;92(3):911-8
   PubMedGoogle Scholar
• Langer RD, Landgren BM, Rimer J, Helmond FA. Effects of tibolone and continuous combined conjugated equine estrogen/medroxyprogesterone acetate on the endometrium and vaginal bleeding: results of the OPAL Study. Am J Obstet Gynecol 2006;195:1320-7
   PubMed Web of Science ®Google Scholar
• Wierk EJ, Hendricks PT, Boerstoel-Streefland M. Clinical background of women prescribed tibolone or combined estrogen and progestogen therapies: a UK Mediplus study. Climacteric 2004;7:197-209
   PubMedGoogle Scholar
• Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003;362:419-27
   PubMed Web of Science ®Google Scholar
• Sendag F, Terek MC, Ozsener S, et al. Mammographic density changes during different postmenopausal hormone replacement therapies. Fertil Steril 2001;76:445-50
   PubMed Web of Science ®Google Scholar
• Egarter C, Eppel W, Vogel S, Wolf G. A pilot study of hormone replacement therapy with tibolone in women with mastopathic breast. Maturitas 2001;40:165-71
   PubMed Web of Science ®Google Scholar
• Speroff L. The Million Women Study and breast cancer [Editorial]. Maturitas 2003;46:1-6
   PubMedGoogle Scholar
• Vanhoecke BE, Bracke ME, Kloosterboer HJ, Depypere HT. Tibolone and its metabolites inhibit invasion of human mammary carcinoma cells in vitro. Maturitas 2006;54:229-37
   PubMedGoogle Scholar
• Gompel A, Chaouat M, Jacob D, et al. In vitro studies of tibolone in breast cells. Fertil Steril 2002;78:351-9
   PubMed Web of Science ®Google Scholar
• Mirkin S, Wong BC, Archer DF. Effect of 17 beta-estradiol, progesterone, synthetic progestins, tibolone, and tibolone metabolites on vascular endothelial growth factor mRNA in breast cancer cells. Fertil Steril 2005;84:485-91
   PubMed Web of Science ®Google Scholar
• Dimitrakakis C, Keramopoulos D, Vourli G, et al. Clinical effects of tibolone in postmenopausal women after 5 years of tamoxifen therapy for breast cancer. Climacteric 2005;8:342-51
   PubMed Web of Science ®Google Scholar
• Kroiss R, Fentiman IS, Helmond FA, et al. The effect of tibolone in postmenopausal women receiving tamoxifen after surgery for breast cancer: a randomised, double-blind, placebo-controlled trial. Br J Obstet Gynecol 2005;112:228-33
   Google Scholar
• Mueck AO, Lippert C, Seeger H, Wallwier D. Effects of tibolone on human breast cancer cells and human vascular coronary cells. Arch Gynecol Obstet 2003;267:139-44
   PubMedGoogle Scholar
• Clemmons M, Goss P. Estrogen and the risk of breast cancer. N Engl J Med 2002;344:276-85
   Google Scholar
• Gingrass S, Cote S, Simard J. Multiple signal transduction pathways mediate interleukin-4-induced 3beta-hydroxysteroid dehydrogenase/Ä5-Ä4 isomerase in normal and tumoral target tissues. J Steroid Biochem Mol Biol 2001;76:213-25
   PubMedGoogle Scholar
• Pasqualini HJR, Chetrite G, Nguyen BL, et al. Estrone-sulfate-sulfatase and 17-beta hydroxysteroid dehydrogenase activities: a hypothesis for their role in the evolution of human breast cancer from hormone dependence to hormone independence. J Steroid Biochem Mol Biol 1995;53:407-12
   PubMed Web of Science ®Google Scholar
• Van de Ven J, Donker G, Sprong M, et al. Effect of tibolone (ORG OD14) and its metabolites on aromatase and estrone sulfatase activity in human breast adipose stromal cells and in MCF-7 and T47D breast cancer cells. J Steroid Biochem Mol Biol 2002;81:237-47
   PubMed Web of Science ®Google Scholar
• Chetrite GS, Kloosterboer HJ, Phillipe JC, et al. Effects of ORG OD14 (livial) and its metabolites in human estrogen sulfotransferase activity in the hormone dependent MCF-7 and T-47D, and the hormone independent MDA-MB-231 breast cancer cell lines. Anticancer Res 1999;19:269-75
   PubMed Web of Science ®Google Scholar
• De Gooyer ME, Kleyn GT, Smits KC, et al. Tibolone: a compound with tissue specific inhibitory effects on sulfatase. Mol Cell Endocrinol 2001;183:55-62
   PubMed Web of Science ®Google Scholar
• Von Eckardstein A, Crook D, Elbers J, et al. Tibolone lowers high density lipoprotein cholesterol by increasing hepatic lipase activity but does not impair cholesterol efflux. Clin Endocrinol 2002;58:49-58
   Google Scholar
• Winkler U, Altkemper B, Helmond FA, Coelingh Bennink HJ. Effects of tibolone and continuous combined hormone replacement therapy on parameters in the clotting cascade: a multicenter, double-blind, randomized study. Fertil Steril 2000;74:10-9
   PubMed Web of Science ®Google Scholar
• Walker DA, James MJ, Muirhead GJ. Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man. Xenobiotica 1999;29:297-310
   PubMed Web of Science ®Google Scholar
• Morris EP, Denton ER, Robinson J, et al. High resolution ultrasound assessment of the carotid artery: its relevance in postmenopausal women and the effects of tibolone on carotid artery ultrastructure. Climacteric 1999;2:13-20
   PubMedGoogle Scholar
• Davison S, Davis SR. New markers for cardiovascular disease risk in the women: impact of endogenous estrogen status and exogenous postmenopausal hormone therapy. J Clin Endocrinol Metab 2003;88:2470-8
   PubMed Web of Science ®Google Scholar
• Visvanathan K, Gallicchio L, Schilling C, et al. Cytochrome gene polymorphisms, serum estrogens and hot flushes in midlife women. Obstet Gynecol 2005;106:1372-81
   PubMed Web of Science ®Google Scholar
• Cummings SR; for LIFT Steering Committee. LIFT study is discontinued. BMJ 2006;332:667
   PubMed Web of Science ®Google Scholar